Endologix, Inc. develops and manufactures minimally invasive treatments for vascular diseases. Endologix's Powerlink System is an endoluminal stent graft (ELG) for treating abdominal aortic aneurysms (AAA). AAA is a weakening of the wall of the aorta, the largest artery in the body, resulting in a balloon-like enlargement. Once AAA develops, it continues to enlarge and, if left untreated, becomes increasingly susceptible to rupture. The overall patient mortality rate for ruptured AAA is approximately 75%, making it the 13th leading cause of death in the United States.
How many people does Endologix employ?
Endologix currently employs 195 people as of June 2008.
What is Endologix's fiscal year-end?
December 31
On which exchange does Endologix trade and what is the symbol?
Endologix is listed on the NASDAQ exchange, and the trading symbol is ELGX.
When did Endologix become public?
Endologix became public through a reverse merger in May 2002.
How many shares are outstanding?
As of June 30, 2008, there were 43,629,000 shares of common stock outstanding.
Does Endologix issue dividends on its common stock?
Endologix does not currently issue dividends.
Does Endologix have a direct stock-purchase plan?
Endologix does not currently have a direct stock-purchase plan.
Who are Endologix's independent auditors?
PricewaterhouseCoopers, LLP
2020 Main Street, Suite 400
Irvine, CA 92614
Who is Endologix's stock-transfer agent?
American Stock Transfer & Trust Company
59 Maiden Lane
New York, NY 10038
Who is Endologix's legal counsel?
Stradling Yocca Carlson & Rauth
660 Newport Center Drive
Newport Beach, CA 92660
(949) 725-4000
Where is Endologix's headquarters?
We are located in Southern California. Our address is:
11 Studebaker
Irvine, CA 92618
Do you have another question that hasn't been answered?
Please submit your question using the form below. Fields marked with an * are required.
Home | 
Contact Us 
Health Care
Professionals 
show all
hide all